Retatrutide Phase 3 results: what the data actually shows

The headline number: 25% body weight reduction

Retatrutide achieved 25% mean body weight reduction at 80 weeks. For context: semaglutide (Wegovy) produces approximately 15%, and tirzepatide (Zepbound) approximately 22%. Retatrutide outperforms every approved obesity drug on the market.

You do not need the highest dose

The lowest dose — 4mg — already outperforms Wegovy, producing 18% weight loss with a single dose escalation. Fewer patients discontinued at lower doses than at the placebo arm. This is significant: it means the drug is tolerable at doses that already exceed the current standard of care.

No plateau at two years

At 80 weeks — approaching two years — patients were still losing weight. No plateau was observed. This is unprecedented in obesity pharmacology. Every previous drug in this class shows a plateau effect where weight loss slows and eventually reverses. Retatrutide's continued downward trajectory is likely explained by its third receptor: glucagon.

Patients with BMI over 35 lost an average of 84 pounds — approximately 30% of their starting body weight.

Some patients stopped because they lost too much weight

A subset of patients on the highest dose discontinued treatment because they had lost too much weight and reached or approached underweight status. This has never been reported with an obesity drug before.

The mechanism: glucagon receptor activation

Tirzepatide and semaglutide suppress appetite through GLP-1 receptor agonism. Retatrutide does this too — but adds glucagon receptor activation as a third mechanism. The glucagon receptor drives the liver to switch fuel sources, burning stored fat rather than dietary carbohydrate.

In Phase 2 data, ketone body levels rose 2–3× in patients on retatrutide — confirming the metabolic switch is occurring.

New side effect: tingling and numbness

12.5% of patients reported tingling and numbness — a side effect not observed with tirzepatide or semaglutide. This is likely related to glucagon receptor activity. Researchers should track this closely in their own data.

The fatty liver finding: 86% clearance

In a dedicated NAFLD sub-study, retatrutide cleared 86% of liver fat. 93% of patients reached normal liver fat levels. 1 in 3 adults have non-alcoholic fatty liver disease. There is no approved drug that treats NAFLD.

Obesity reclassification: two-thirds of patients

Among patients on the highest dose, two-thirds were reclassified out of obesity entirely. They started the trial at a mean BMI of approximately 40. They finished under 30.

FDA timeline

Eli Lilly is expected to file for FDA approval in late 2026. Standard review timelines suggest an approval decision in late 2027.